Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

BMY
Bristol-Myers Squibb Co.
stock NYSE

At Close
May 9, 2025 3:59:59 PM EDT
46.44USD-0.939%(-0.44)14,915,367
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 9, 2025 9:26:30 AM EDT
46.90USD+0.043%(+0.02)8,325
After-hours
May 9, 2025 4:54:30 PM EDT
46.40USD-0.086%(-0.04)49,884
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsDividendsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 28, 2022
12:32PM EST  EMA's Advisory Committee Recommends Approval Of Bristol-Myers' Breyanzi In Lymphoma   Benzinga
07:00AM EST  Bristol Myers Squibb Receives Positive CHMP Opinion For CAR T Cell Therapy Breyanzi For Relapsed Or Refractory DLBCL, PMBCL And FL3B   Benzinga
Jan 26, 2022
08:29AM EST  The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data   Benzinga
Jan 20, 2022
06:26AM EST  Bristol Myers Squibb Receives Approval For Abecma, The First CAR T Therapy Approved For The Treatment Of Multiple Myeloma In Japan   Benzinga
Jan 13, 2022
11:47AM EST  Prellis Biologics Announces Collaboration And License Agreement With Bristol Myers Squibb; Prellis To Receive Undisclosed Upfront Payment, Funding For Research And Milestones   Benzinga
11:47AM EST  The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact   Benzinga
Jan 11, 2022
01:55PM EST  Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum   Benzinga
08:36AM EST  The Daily Biotech Pulse: Illumina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In   Benzinga
07:08AM EST  Biomica : Israel Clears First-in-Human Phase I Study Of BMC-128 In Combination With Bristol Myers' Anti-PD-1 Opdivo   RTTNews
07:04AM EST  Evogene's Biomica Announces Clearance For First-In-Human Phase I Study Of BMC-128 In Combination With Bristol Myers Squibb's Anti-PD-1 Opdivo   Benzinga
05:29AM EST  Evotec Announced Expansion of Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach   Benzinga
02:02AM EST  Evotec AG (EVTCY.PK), a drug discovery and development company, announced Tuesday that it has expanded its neurodegeneration collaboration with Bristol Myers Squibb (BMY) to include a new targeted protein degradation approach.   RTTNews
01:48AM EST  Evotec Expands Neuroscience Collaboration With Bristol Myers Squibb   RTTNews
Jan 10, 2022
04:07PM EST  BioAtla Announces Clinical Collaboration With Bristol Myers Squibb To Study Mecbotamab Vedotin And Ozuriftamab Vedotin In Combination With Opdivo For Treatment Of Solid Tumors   Benzinga
04:05PM EST  Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo(r) (nivolumab) for Treatment of Solid Tumors   PR Newswire
12:32PM EST  Bristol-Myers Squibb CEO Now Appearing On CNBC   Benzinga
10:47AM EST  Bristol Myers Squibb CEO To Appear On CNBC's Halftime Report   Benzinga
07:02AM EST  Century Therapeutics And Bristol Myers Squibb Enter Into A Strategic Collaboration To Develop iPSC-derived Allogeneic Cell Therapies   Benzinga
06:56AM EST  Bristol-Myers Squibb's Debt Overview   Benzinga
06:49AM EST  Bristol-Myers Squibb Sees FY22 Revlimid Sales Results Of $9.5B-$10B   Benzinga
06:48AM EST  Bristol Myers Squibb Announces $5B Accelerated Buyback; Sees FY22 Sales Of ~$47B Vs. $47.75B Est., Sees FY22 EPS $7.65-$7.95 Vs. $7.84 Est.   Benzinga
Dec 19, 2021
12:54PM EST  The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week   Benzinga
Dec 17, 2021
10:18AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021   Benzinga
07:37AM EST  Goldman Sachs Initiates Coverage On Bristol-Myers Squibb with Buy Rating, Announces Price Target of $72   Benzinga
Dec 16, 2021
06:57AM EST  Bristol Myers Squibb's Orencia has received approval from the U.S. Food and Drug Administration for prophylaxis or prevention of acute graft versus host disease or aGVHD.   RTTNews
05:49AM EST  FDA Approves Bristol Myers' Orencia As First Drug To Prevent Graft-Versus-Host Disease   Benzinga
Dec 15, 2021
12:12PM EST  Bristol Myers Shares Quiet; Co. Wins FDA Approval For Orencia   Benzinga
11:48AM EST  Bristol Myers Shares Quiet; Hearing Co. Wins FDA Approval For Orencia   Benzinga
08:03AM EST  Exelixis Announces Initiation Of Phase 1b Trial Evaluating XL092 In Combination With Immuno-oncology Therapies In Patients With Advanced Solid Tumors   Benzinga
Dec 14, 2021
07:01AM EST  Immatics And Bristol Myers Squibb Enter Into Global Exclusive License For Immatics' TCR Bispecific Program; Immatics To Receive $150M Upfront Payment And Additional Milestones Of Up To $770M   Benzinga
Dec 13, 2021
04:38PM EST  Bristol-Myers Filing Shows Registration For Mixed Securities Shelf Offering, No Terms Disclosed   Benzinga
12:12PM EST  Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients   Benzinga
07:57AM EST  Bristol Myers Board Approves Increase In Quarterly   RTTNews
07:24AM EST  Bristol Myers Squibb Lifts Quarterly Dividend To $0.54; Announces Addl $15 Bln Share Buyback   RTTNews
06:24AM EST  Bristol Myers Reveals Full Data For Breyanzi In Second-Line Lymphoma Setting   Benzinga
Dec 12, 2021
10:06PM EST  Antengene Corp. said that it has reached a clinical trial collaboration to evaluate the safety, pharmacokinetics and preliminary efficacy of ATG-017 in combination with Bristol Myers Squibb's PD-1 checkpoint inhibitor, Opdivo or nivolumab.   RTTNews
04:56PM EST  The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More   Benzinga
Dec 10, 2021
11:26AM EST  Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial   Benzinga
Dec 9, 2021
09:51PM EST  Where Bristol-Myers Squibb Stands With Analysts   Benzinga
09:50PM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021   Benzinga
09:47PM EST  Wells Fargo Initiates Coverage On Bristol-Myers Squibb with Equal-Weight Rating, Announces Price Target of $58   Benzinga
Dec 3, 2021
10:50PM EST  BRISTOL MYERS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Bristol-Myers Squibb Company - BMY   Business Wire
11:05AM EST  Bristol Myers - Merck's Thalassemia Candidate Under FDA Priority Review   Benzinga
07:40AM EST  The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering   Benzinga
07:00AM EST  Bristol Myers Squibb Reports FDA Accepted For Priority Review Supplemental Biologics License Application For Reblozyl In Adults With Non-Transfusion Dependent Beta Thalassemia   Benzinga
Dec 2, 2021
12:02PM EST  Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates   Benzinga
Dec 1, 2021
11:17PM EST  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
07:53PM EST  CLAIMSFILER ALERTS BRISTOL MYERS Investors to Lead Plaintiff Deadline in Class   PR Newswire
Nov 30, 2021
11:34PM EST  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
04:58PM EST  Mereo BioPharma's Etigilimab/Opdivo Combo Achieves One Complete Response In Cervical Cancer   Benzinga
04:02PM EST  Bristol Myers' Deucravacitinib Under FDA Review For Plaque Psoriasis   Benzinga
Nov 29, 2021
11:44PM EST  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
08:13AM EST  Bristol Myers Squibb (BMY) announced Monday that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis.   RTTNews
07:54AM EST  Bristol Myers Squibb Says Applications For Deucravacitinib Accepted By FDA And Validated By EMA   RTTNews
07:00AM EST  Bristol Myers Squibb's Applications For Deucravacitinib For The Treatment Of Moderate To Severe Plaque Psoriasis Accepted By U.S. Food and Drug Administration And Validated By European Medicines Agency   Benzinga
Nov 24, 2021
11:35PM EST  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
12:06AM EST  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
Nov 23, 2021
11:46AM EST  Bristol Myers' Zeposia Wins European Approval For Ulcerative Colitis   Benzinga
08:35AM EST  Bristol's Zeposia Gets Market Authorization From European   RTTNews
08:10AM EST  The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug   Benzinga
07:00AM EST  Bristol Myers Squibb Receives European Commission Approval Of Zeposia (ozanimod) For Use In Adults With Moderately To Severely Active Ulcerative Colitis   Benzinga
Nov 22, 2021
10:56PM EST  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Nov 19, 2021
10:00PM EST  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
12:33PM EST  Bristol Myers' Mavacamten Added Via $13B Myokardia Buyout, Hit By FDA Delay   Benzinga
11:56AM EST  What 5 Analyst Ratings Have To Say About Bristol-Myers Squibb   Benzinga
10:09AM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021   Benzinga
08:20AM EST  The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial   Benzinga
06:59AM EST  Bristol Myers Squibb Reports FDA Has Extended Review Of New Drug Application for Mavacamten To Apr. 28, 2022   Benzinga
05:37AM EST  BMO Capital Initiates Coverage On Bristol-Myers Squibb with Outperform Rating, Announces Price Target of $72   Benzinga
Nov 18, 2021
10:50PM EST  FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of   PR Newswire
07:55AM EST  Berkshire Exited Merck Before COVID Pill Boost; Trimmed Holdings In AbbVie, Bristol Myers In Q3   Benzinga
Nov 17, 2021
11:50PM EST  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Nov 16, 2021
04:29PM EST  Bristol Myers CEO Says Patients Seeking Cancer Care Below Pre-COVID Level   Benzinga
Nov 15, 2021
11:26AM EST  Bristol-Myers Squipp Says Late-Breaking Phase 2 Data For Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across Wide Range Of Doses   Benzinga
10:50AM EST  Bristol Myers Rolls Out Long-Term Data For Mavacamten In Heart Disease   Benzinga
10:37AM EST  The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More   Benzinga
Nov 12, 2021
10:50PM EST  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Nov 11, 2021
08:03AM EST  The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts   Benzinga
07:03AM EST  Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment   Benzinga
07:02AM EST  Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Million Equity Investment PR Newswire - Nov 11 07:00 EDT   Benzinga
Nov 10, 2021
04:00AM EST  Evotec Reaches Additional Programme Designations Within   RTTNews
03:03AM EST  Evotec Reaches Programme Designations In Neuroscience Collaboration With Bristol Myers Squibb   RTTNews
Nov 8, 2021
11:18AM EST  UPDATE: SVB Leerink On Nektar Price Target Cut: Believes 'Likelihood Of Failure For Bempeg In Lead Indications Is Higher Than Typical For Phase 3 Trials'; Remains Positive On Partnership Terms Of Bristol-Myers Deal As Co. Retains 65% Of Profits   Benzinga
10:13AM EST  Bristol Myers' Opdivo Combo Meets Endpoint Goal In Lung Cancer Trial   Benzinga
08:29AM EST  The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More   Benzinga
07:03AM EST  Bristol Myers Squibb Announces Phase 3 CheckMate-816 Trial Met its Primary Endpoint   Benzinga
Nov 5, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Nov 4, 2021
09:25PM EDT  FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of   PR Newswire
10:17AM EDT  Bristol Myers Squibb To Highlight More Than 80 Abstracts At ASH 2021   Benzinga
02:14AM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Nov 2, 2021
02:09PM EDT  Bristol-Myers Squibb's OPDIVO Receives 2 New Health Canada Approvals   Benzinga
02:04PM EDT  for the Treatment for Patients with HER2 Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma Cancers; Use as Monotherapy for the Adjuvant Treatment for Patients with Completely Resected Esophageal or Gastroesophageal Junction Cancers   PR Newswire
09:00AM EDT  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors.   GlobeNewswire Inc
Nov 1, 2021
10:45PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
12:17PM EDT  Expert Ratings For Bristol-Myers Squibb   Benzinga
08:42AM EDT  Argus Research Downgrades Bristol-Myers Squibb to Hold   Benzinga
07:27AM EDT  New Data Reaffirms Merck's Keytruda In Extending Survival In Melanoma Patients   Benzinga
Oct 29, 2021
10:50PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Oct 28, 2021
09:43AM EDT  Barclays Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $66   Benzinga
Oct 27, 2021
09:21AM EDT  Bristol Myers Q3 Earnings In-line With Expectations, Raises Lower End Of FY21 Adjusted EPS Outlook   Benzinga
07:28AM EDT  While reporting financial results for the third quarter on Wednesday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) raised its adjusted earnings guidance for the full-year 2021.   RTTNews
07:04AM EDT  Bristol Myers Squibb Q3 EPS $0.69 And Non-GAAP EPS $2.00   RTTNews
07:04AM EDT  UPDATE: Bristol Myers Raises Lower End Of FY21 Adj. EPS Guidance From $7.35-$7.55 To $7.40-$7.55 vs $7.47 Estimate   Benzinga
07:00AM EDT  Bristol-Myers Squibb Q3 Adj. EPS $2.00 Beats $1.92 Estimate, Sales $11.62B Beat $11.58B Estimate; Raises Low End Of FY21 Adj. EPS Guidance   Benzinga
03:43AM EDT  Earnings Scheduled For October 27, 2021   Benzinga
Oct 25, 2021
06:50AM EDT  TCR Therapeutics Announces Clinical Trial Collaboration Agreement With Bristol Myers Squibb To Evaluate Gavo-cel In Combination With Opdivo And Yervoy In Mesothelin-Expressing Solid Tumors   Benzinga
06:45AM EDT  TCR Therapeutics Announces Clinical Trial   GlobeNewswire Inc
Oct 24, 2021
11:45AM EDT  The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More   Benzinga
Oct 22, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
03:51PM EDT  'Bristol-Myers Said To Make Takeover Approach To Aurinia'- Bloomberg   Benzinga
Oct 21, 2021
01:11PM EDT  Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg   Benzinga
12:11PM EDT  The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO   Benzinga
12:11PM EDT  Bristol Myers Squibb Receives European Commission Approval For Opdivo + Chemotherapy For Patients With HER2 Negative, Advanced Or Metastatic Gastric, Gastroesophageal Junction Or Esophageal Adenocarcinoma   Benzinga
12:11PM EDT  Bloomberg Reported Late Wednesday Bristol-myers Squibb Plans to Tender Its Shares in Acceleron Pharma Following Merck Agreement to Acquire the Biotech Company   Benzinga
Oct 19, 2021
11:05PM EDT  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
08:23AM EDT  The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio   Benzinga
Oct 18, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
Oct 15, 2021
10:50PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
07:00AM EDT  Bristol Myers Squibb Reports Received Positive CHMP Opinion For Zeposia As Treatment For Adults With Moderately To Severely Active Ulcerative Colitis   Benzinga
Oct 14, 2021
12:00PM EDT  This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers   Benzinga
Oct 13, 2021
10:36PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
01:38PM EDT  Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia in Patients with Relapsing Forms of Multiple Sclerosis   Benzinga
Oct 12, 2021
10:36PM EDT  The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.   GlobeNewswire Inc
09:33AM EDT  MINDCURE's "Desire Project" uses MDMA to Treat Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women   Benzinga
08:18AM EDT  Morgan Stanley Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $66   Benzinga
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 11, 2021
10:47PM EDT  Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
08:57AM EDT  Berenberg Maintains Buy on Bristol-Myers Squibb, Lowers Price Target to $71   Benzinga
Oct 8, 2021
10:50PM EDT  ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:   GlobeNewswire Inc
09:37AM EDT  Evotec Expands Neuroscience Collaboration with Bristol Myers   Benzinga
08:46AM EDT  Barclays Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $68   Benzinga
03:07AM EDT  Evotec Expands Neuroscience Collaboration With Bristol Myers Squibb To Include Novel Cell Type   RTTNews
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
08:07AM EDT  Bristol Myers Squibb (BMY) on Thursday said its Phase 2 study of deucravacitinib dubbed LATTICE-UC in moderate to severe ulcerative colitis (UC) did not meet the primary efficacy endpoint.   RTTNews
07:44AM EDT  Bristol Myers Squibb: LATTICE-UC Proof Of Concept Study Not To Meet Primary Nor Secondary Endpoints   RTTNews
07:00AM EDT  UPDATE: Bristol Myers Squibb Announces Phase 2 LATTICE-UC Study Did Not Meet The Primary Efficacy Endpoint Of Clinical Remission At Week 12, Nor Secondary Efficacy Endpoints   Benzinga
07:00AM EDT  Bristol Myers Squibb Provides Update On Phase 2 Study Of Deucravacitinib In Patients With Moderate To Severe Ulcerative Colitis   Benzinga
Oct 6, 2021
06:44PM EDT  Entwistle & Cappucci LLP Files a Securities Class Action Complaint Against Bristol-Myers Squibb Company   Business Wire
12:30AM EDT  Cannabis Movers & Shakers: TOCC, 1933 Industries, Iter Investments, Greenlane   Benzinga
Oct 1, 2021
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
07:05AM EDT  Bristol Myers Squibb to Hold Investor Event on November 16   Business Wire
07:01AM EDT  European Medicines Agency Validates Bristol Myers Squibb's Application For Mavacamten For Treatment Of Obstructive Hypertrophic Cardiomyopathy   Benzinga
Sep 28, 2021
12:54PM EDT  Bristol-Myers Squibb Option Alert: Oct 8 $60 Calls Sweep (23) near the Ask: 759 @ $0.62 vs 386 OI; Earnings 10/27 Before Open Ref=$59.63   Benzinga
08:13AM EDT  AstraZeneca's Saphnelo For Lupus Treatment Approved In Japan   Benzinga
Sep 27, 2021
10:22AM EDT  Bristol Myers' Two Opdivo Based Regimes Under FDA Review For Esophageal Cancer   Benzinga
08:23AM EDT  Bristol Myers: FDA Accepts SBLA For Opdivo Plus Yervoy,   RTTNews
07:55AM EDT  FDA Accepts Bristol Myers' SBLA For Opdivo + Yervoy And Opdivo + Chemotherapy In Esophageal Squamous Cell Carcinoma   RTTNews
07:11AM EDT  FDA Accepts Bristol Myers Squibb's Applications For Opdivo + Yervoy And Opdivo + Chemotherapy For Unresectable Advanced, Recurrent Or Metastatic Esophageal Squamous Cell Carcinoma   Benzinga
05:53AM EDT  Acceleron In Advanced $11B Buyout Talks: Bloomberg   Benzinga
Sep 23, 2021
03:48PM EDT  Early JW Therapeutics Backer Ruins Regulatory Breakthrough Party With Stake Sale   Benzinga
Sep 20, 2021
08:24AM EDT  Bristol Myers Reports FDA Priority Review For Relatlimab   RTTNews
07:48AM EDT  Bristol Myers Gets FDA Priority Review For Relatlimab/Opdivo Fixed-dose Combination In Melanoma   RTTNews
07:00AM EDT  U.S. FDA Accepts For Priority Review Bristol Myers Squibb's Application For LAG-3-Blocking Antibody Relatlimab And Nivolumab Fixed-Dose Combination As Treatment For Patients With Unresectable or Metastatic Melanoma   Benzinga
Sep 19, 2021
09:46AM EDT  The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions and Conference Presentations In The Spotlight   Benzinga
Sep 17, 2021
07:03AM EDT  Gristone Reports Clinical Data With GRANITE During European Society Of Medical Oncology, Launch Of Randomized Clinical Trial Program For Colorectal Cancer With Registrational Intent   Benzinga
07:00AM EDT  Bristol Myers Reports Positive CHMP Opinion For Opdivo + Chemo For Patients With HER2-Negative Advanced, Metastatic Gastric , Gastroesophageal Junction, Esophageal Adenocarcinoma Whose Tumors Express PD-L1 With CPS   Benzinga
Sep 16, 2021
03:13PM EDT  These Industries Stand To Benefit From The Infrastructure Bill And These Companies Are Lobbying Against It   Benzinga
03:13PM EDT  These Industries Stand to Benefit from the Infrastructure Bills' Passage And These Companies Are Lobbying Against It   Benzinga
02:01PM EDT  Bristol Myers Touts 5-Year Kidney Cancer Data For Opdivo-Yervoy Combo Therapy   Benzinga
07:51AM EDT  Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery   Benzinga
07:00AM EDT  Bristol Myers Squibb Announces Five-Year Data from CheckMate -214 Show Opdivo Plus Yervoy Demonstrates Longest Median Overall Survival Currently Reported In Phase 3 Trial Of Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma   Benzinga
Sep 13, 2021
11:02AM EDT  Bristol Myers' Immunotherapy Combo Shows Durable Survival At Three Years In MPM Setting   Benzinga
07:01AM EDT  Bristol Myers Squibb Announces Three-Year Data From CheckMate -743 Trial Demonstrating 'Durable Overall Survival at Three Years Compared to Chemotherapy in First-Line Unresectable Malignant Pleural Mesothelioma'   Benzinga
Sep 8, 2021
07:32AM EDT  The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod   Benzinga
07:30AM EDT  Bolt Biotherapeutics Announces Clinical Collaboration with Bristol   GlobeNewswire Inc
07:00AM EDT  Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-Stage Cancers   Benzinga
Sep 5, 2021
01:14PM EDT  The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week   Benzinga
Sep 3, 2021
02:10PM EDT  Bristol-Myers Squibb-Pfizer Alliance Pleased With Decision By U.S. Court Of Appeals For Federal Circuit Upholding Eliquis Patents   Benzinga
12:50PM EDT  Wall Street Crime And Punishment: Martha Stewart's Perfectly Ridiculous Stock Scandal   Benzinga
Sep 2, 2021
09:46AM EDT  Bristol Myers Exercises Option In-License Evotec's Neurodegenerative Candidate   Benzinga
08:35AM EDT  FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know   Benzinga
08:20AM EDT  The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab   Benzinga
01:59AM EDT  Evotec SE (EVTCY.PK, EVOTF.PK), a German drug discovery alliance and development partnership company, Thursday announced that Bristol Myers Squibb Co. (BMY) has exercised its option to enter into an exclusive global license for EVT8683.   RTTNews
01:36AM EDT  Evotec: Bristol Myers Squibb Exercises Option To Enter Into Global License For EVT8683   RTTNews
Aug 30, 2021
08:27AM EDT  UK's NICE Rejects Johnson & Johnson's Darzalex Regime For Newly Diagnosed Myeloma   Benzinga
Aug 27, 2021
07:35AM EDT  The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration   Benzinga
Aug 26, 2021
12:58PM EDT  Gilead Wins Reversal of $1.2B Patent Loss to Bristol-Myers: Bloomberg   Benzinga
07:52AM EDT  Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer   Benzinga
Aug 24, 2021
08:09AM EDT  The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal   Benzinga
Aug 23, 2021
07:01AM EDT  Bristol Myers Squibb's Orencia for the Prevention of Acute Graft Versus Host Disease Granted Priority Review by the FDA   Benzinga
Aug 20, 2021
01:38PM EDT  Bristol Myers Scores FDA Approval For Opdivo In Postsurgery Bladder Cancer   Benzinga
11:45AM EDT  FDA Approves Opdivo (nivolumab) For Adjuvant Treatment Of Patients With High-Risk Urothelial Carcinoma   Benzinga
Aug 19, 2021
03:34PM EDT  Europe Approves Bristol Myers' BCMA-Targeted Multiple Myeloma Immunotherapy   Benzinga
09:35AM EDT  Bristol Myers Squibb Receives European Commission Approval For Abecma (Idecabtagene Vicleucel)   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 16, 2021
01:26PM EDT  Novavax Appoints New CFO Amid Inordinate Delay In COVID-19 Vaccine Authorization   Benzinga
Aug 10, 2021
02:42PM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
Aug 6, 2021
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Aug 3, 2021
05:42PM EDT  'Fast Money Halftime Report' Picks For August 3   Benzinga
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
Aug 2, 2021
07:14AM EDT  AstraZeneca' Saphnelo Wins FDA Nod For Systemic Lupus Erythematosus, Marking New Treatment Approval In 10 Years   Benzinga
Aug 1, 2021
11:19AM EDT  The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs   Benzinga
Jul 30, 2021
09:05AM EDT  Bristol Myers' Opdivo Scores European Approval As Adjuvant Treatment For Gastric Cancer   Benzinga
07:54AM EDT  The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs   Benzinga
07:01AM EDT  Bristol Myers Reports European Commission Approval For Co.'s Opdivo As Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy   Benzinga
Jul 29, 2021
08:30AM EDT  Morgan Stanley Maintains Equal-Weight on Bristol-Myers Squibb, Raises Price Target to $71   Benzinga
Jul 28, 2021
07:42AM EDT  Bristol Myers Q2 Earnings Slightly Ahead Of Estimates, Trims FY21 GAAP EPS Guidance   Benzinga
07:41AM EDT  While reporting financial results for the second quarter on Wednesday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) reaffirmed its adjusted earnings and revenue growth guidance for the full-year 2021.   RTTNews
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
07:22AM EDT  Recap: Bristol-Myers Squibb Q2 Earnings   Benzinga
07:09AM EDT  Bristol-Myers Q2 EPS $0.47 And Non-GAAP EPS $1.93   RTTNews
07:00AM EDT  Bristol Myers Squibb Reaffirms FY21 Adj. EPS Guidance Range Of $7.35-$7.55 vs $7.46 Est.   Benzinga
06:59AM EDT  Bristol-Myers Squibb Q2 Adj. EPS $1.93 Beats $1.91 Estimate, Sales $11.70B Beat $11.33B Estimate   Benzinga
04:27AM EDT  Earnings Scheduled For July 28, 2021   Benzinga
Jul 27, 2021
11:13AM EDT  Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings   Benzinga
11:13AM EDT  BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb To Study BBP-398 In Combination With OPDIVO In Advanced Solid Tumors With KRAS Mutations   Benzinga
Jul 26, 2021
12:21PM EDT  Bristol Myers Pulls Accelerated Approval For Opdivo In Post-Nexavar Liver Cancer   Benzinga
Jul 25, 2021
10:05AM EDT  The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More   Benzinga
Jul 23, 2021
07:45AM EDT  The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs   Benzinga
Jul 19, 2021
02:32PM EDT  Analysts See Higher Success Chances For Cytokinetics' Heart Disease Candidate After Positive Phase 2 Data   Benzinga
Jul 16, 2021
01:54PM EDT  Bristol-Myers Squibb Reports CheckMate -651 Trial For Opdivo Plus Yervoy For Squamous Cell Carcinoma Of Head And Neck Did Not Meet Primary Endpoint   Benzinga
08:05AM EDT  Bristol-Myers' Opdvio/Yervoy Combo Therapy Flunks In Head & Neck Cancer Trial   Benzinga
07:56AM EDT  Bristol Myers Squibb (BMY) said that phase 3 CheckMate-651 trial, which evaluated opdivo or nivolumab plus yervoy or ipilimumab versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and Neck, did not meet its primary endpoints.   RTTNews
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
07:00AM EDT  Bristol-Myers Squibb Reports CheckMate -651 Trial For Opdvio Plus Yervoy For Squamous Cell Carcinoma Of Head And Neck Did Not Meet Primary Endpoint   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
06:38AM EDT  XOMA Buys Royalty, Milestone Interest In Checkmate's Vidutolimod From Kuros Biosciences   Benzinga
Jul 8, 2021
10:00AM EDT  After Second Look Oncopeptides' Melflufen Wins Head-To-Head Myeloma Trial, But Difference In OS Triggers FDA Hold   Benzinga
Jul 7, 2021
07:58AM EDT  OncoSec Stock Jumps On Anti-Cancer Gene Therapy Trial Collaboration With Merck In Melanoma   Benzinga
Jun 29, 2021
07:38AM EDT  Bristol Myers Squibb (BMY) said that the European Commission has approved Opdivo or nivolumab plus Yervoy or ipilimumab for the treatment of adult patients with mismatch repair deficient or dMMR or microsatellite instability-high or MSI-H metastatic colorectal cancer or mCRC after prior fluoropyrimidine-based combination chemotherapy.   RTTNews
07:28AM EDT  Bristol Myers Squibb Receives European Commission Approval For Opdivo Plus Yervoy For The Treatment Of Mismatch Repair Deficient Or Microsatellite InstabilityHigh Metastatic Colorectal Cancer After Prior Chemotherapy   Benzinga
07:19AM EDT  Bristol Myers Squibb: EU Approves Opdivo+ Yervoy For Adult Patients With Mismatch Repair Deficient   RTTNews
Jun 25, 2021
07:48AM EDT  Bristol Myers Gets Positive CHMP Opinion For Abecma On   RTTNews
07:40AM EDT  Bristol Myers Squibb (BMY) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has recommended approval of Opdivo or nivolumab for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction or GEJ cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy or CRT.   RTTNews
07:32AM EDT  The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs   Benzinga
07:27AM EDT  Bristol Myers Squibb Gets Positive CHMP Opinion For Anti-BCMA CAR T Cell Therapy Abecma   RTTNews
07:27AM EDT  Bristol Myers Squibb Gets Positive CHMP Opinion For Opdivo   RTTNews
06:59AM EDT  Bristol Myeres Reports Positive CHMP Opinion For Opdivo As Adjuvant Treatment For Esophageal, Gastroesophageal Junction Cancer Patients With Residual Pathologic Disease Following Chemoradiotherapy   Benzinga
06:55AM EDT  Bristol Myers Reports Positive CHMP Opinion For Anti-B-Cell Mutation Antigen CAR T Cell Therapy Abecma For Relapsed, Refractory Multiple Myeloma   Benzinga
Jun 24, 2021
08:59AM EDT  Bristol Myers Squibb exercised its option under the global neuroscience research and development collaboration to enter into an exclusive U.S. license for PRX005. Bristol Myers will pay Prothena $80 million, Prothena Corporation plc (PRTA) said in a statement.   RTTNews
08:43AM EDT  Prothena To Receive $80 Mln From Bristol Myers Squibb For Exclusive US License To PRX005   RTTNews
08:32AM EDT  Prothena Announces Bristol Myers Squibb Opt-In Of Anti-Tau PRX005 As First Program From Global Neuroscience Research And Development Collaboration   Benzinga
Jun 18, 2021
01:25PM EDT  Bristol Myers Onureg Scores European Approval As Maintenance Therapy For Acute Myeloid Leukemia   Benzinga
09:35AM EDT  Bristol Myers Reports Received European Commission Approval For Onureg As Frontline Oral Maintenance Therapy For Adults With Acute Myeloid Leukemia   Benzinga
07:46AM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
07:05AM EDT  Bristol Myers Inks Licensing Pact For Eisai's Folate Receptor ADC Drug, Lays Out Over $3B For Rights   Benzinga
Jun 17, 2021
11:16PM EDT  Bristol-Myers Squibb Co. (BMY) and Eisai Co., Ltd. have reached a strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate or ADC.   RTTNews
Jun 14, 2021
08:34AM EDT  Exelixis Inc. (EXEL) said Monday that it has reached a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Co. (BMY) for STELLAR-002, a new phase 1b trial evaluating XL092 in combination with immuno-oncology therapies in advanced solid tumors.   RTTNews
08:14AM EDT  Exelixis Announces Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb For STELLAR-002   RTTNews
07:35AM EDT  Johnson & Johnson Building Case With New Patient Survival Data For Darzalex In Multiple Myeloma   Benzinga
Jun 11, 2021
05:43AM EDT  Bristol Myers Squibb (BMY) and Acceleron Pharma Inc. (XLRN) announced Friday the first data from the Phase 2 BEYOND study evaluating Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation agent, plus best supportive care in adult patients with non-transfusion dependent or NTD beta thalassemia.   RTTNews
05:04AM EDT  Bristol Myers Squibb And Acceleron Pharma Present First Data From Phase 2 BEYOND Study On Reblozyl   RTTNews
Jun 10, 2021
08:13AM EDT  The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal   Benzinga
07:59AM EDT  Bristol Myers Squibb (BMY) announced Thursday positive topline results from Phase 3 TRANSFORM trial evaluating Breyanzi (lisocabtagene maraleucel) versus chemotherapy followed by stem cell transplant in second-line relapsed or refractory large B-cell lymphoma or LBCL.   RTTNews
07:05AM EDT  Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021   Business Wire
07:04AM EDT  Bristol Myers Squibb Says Phase 3 TRANSFORM Trial Met Primary And Key Secondary Endpoints   RTTNews
07:00AM EDT  Bristol Myers Squibb Announces Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma Met The Primary Endpoint   Benzinga
Jun 8, 2021
07:12AM EDT  NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 and Opdivo   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC